Skip to main content
. Author manuscript; available in PMC: 2023 Oct 11.
Published in final edited form as: Melanoma Res. 2021 Jun 1;31(3):197–207. doi: 10.1097/CMR.0000000000000734

Figure 2 – Responses to Hsp90i+MAPKi combinations –

Figure 2 –

A) All Hsp90i, (listed left to right) KU758, WGA-TA, and XL888, showed a decrease in UACC-257 cell viability after treatment with Ve (top) or Cb (bottom). Each plot shows the percent of cell viability relative to control and illustrates the corresponding combination effect (e.g. synergistic, additive, or antagonistic) on a color spectrum. The most synergistic combinations were observed in KU758+Ve and KU758+Cb. All six Hsp90i+MAPKi combination abbreviations are tabulated. B and C) The expression of cleaved PARP increased in all inhibitor combinations compared to each drug alone. D) Cell-cycle analysis of UACC-257 by flowcytometry after drug treatments.